Additionally, GSK126, a common EZH2 inhibitor, is an effective treatment both in monolayer systems as well as xenografts in various types of cancers, decreasing proliferation, angiogenesis and increasing apoptosis [57,58]. Here, EZH2 is linked to cancer.